Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Humana AB (0RF7) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Humana AB SEK 56.30, price SEK 72.70, upside -22.6%, quality 56 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
HA
Some data
Sep 24, 2026
Humana AB
0RF7 · LSEOvervalued / MonitorQuality is not strong enough to offset the price risk.
!Fair value kr 56.30 · Overvalued (−22.6%)
!Quality 56/100
!Mixed Growth (revenue 5y +7.5 %/yr)
!Thin margins · 1.7% net margin (TTM)
✓Moderate debt · generates free cash flow
✓1.9% dividend yield · Well covered
!Narrow moat 30/100
!Evidence only medium, so the estimate is less certain
Watch Humana AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range kr 11.88 – kr 79.69 · fair‑value band kr 54.65 – kr 70.38 · the kr 72.70 price screens above the kr 56.30 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Company profile
Humana AB (publ) provides individual and family care services for children and adults in Sweden, Finland, Norway, and Denmark. The company operates through three segments: Sweden, Finland, and Norway.
Show more
Humana AB (publ) provides individual and family care services for children and adults in Sweden, Finland, Norway, and Denmark. The company operates through three segments: Sweden, Finland, and Norway. It provides care and treatment for psychosocial disorders, mental illness, and functional impairment; residential care homes; family care services; short-term, short term housing, day care, and special service housing; outpatient care; assisted living homes; and specially adapted housing for individuals with functional impairments. The company also offers care services and assistance to individuals with permanent functional impairments. In addition, it provides elderly care home services, special service housing, and personal assistance to individuals with permanent functional impairments. Humana AB (publ) was founded in 2001 and is headquartered in Stockholm, Sweden.
Stock analysis
Humana AB (0RF7) currently trades at kr 72.70, while our model-based Fair Value estimate is kr 56.30, 22.6% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 85.27 per share, and 12 of the 25 models we run sit above the kr 72.70 price.
Bear case: the Dividend Discount group reads lowest at kr 7.52, and 13 of the 25 models stay below the price. Evidence for this calculation is medium.
Scenario range: kr 54.65 (bear) to kr 70.38 (bull), the price of kr 72.70 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Humana AB reported revenue of 9.6B SEK in FY2023 versus 7.4B SEK in FY2019, a compound +6.7%/yr. Reported net income was 176M SEK in FY2023, compounding −1.6%/yr from FY2019.
Key figures
Market cap 3.5B SEK (≈ $346M) · P/E ratio 0.1 · EPS (TTM) kr 5.00 · Dividend yield 1.9% · Net margin 1.8% · Return on equity 5.5% · Return on assets (EBIT) 4.8% · Operating margin 1.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 85% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −23%, 0RF7 screens richer than that median.
Fair Value models
Bear kr 54.65
Fair Value kr 56.30
Bull kr 70.38
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
kr 56.17
kr 86.09
kr 124.27
80
Growth DCF
kr 56.06
kr 81.56
kr 111.93
79
Residual Income
kr 38.69
kr 38.00
kr 39.72
76
All 25 models by family
DCF Models
FCF DCF
kr 56.17
kr 86.09
kr 124.27
80
5Y Revenue Exit
kr 50.26
kr 85.27
kr 129.58
71
5Y EBITDA Exit
kr 106.31
kr 191.46
kr 292.06
74
5Y P/E Exit
kr 42.88
kr 71.28
kr 100.83
70
10Y Revenue Exit
kr 50.47
kr 80.15
kr 119.53
66
10Y EBITDA Exit
kr 82.70
kr 143.61
kr 226.74
67
10Y P/E Exit
kr 47.89
kr 71.79
kr 100.56
64
Earnings-Based
Graham-Dodd
kr 22.52
kr 75.20
kr 100.68
64
Lynch FV
kr 17.06
kr 24.38
kr 31.69
61
PEG = 1.0
kr 17.06
kr 24.38
kr 31.69
57
EPV
kr 28.18
kr 33.42
kr 37.68
74
Dividend Discount
Gordon GGM
kr 4.85
kr 8.12
kr 10.54
68
DDM Multi-Stage
kr 4.85
kr 7.52
kr 8.74
67
Multiples
P/E Multiple
kr 54.65
kr 72.86
kr 91.08
63
P/S Multiple
kr 42.23
kr 56.30
kr 70.38
58
P/B Multiple
kr 42.23
kr 56.30
kr 70.38
55
EV/EBIT
kr 75.19
kr 105.42
kr 135.65
66
EV/EBITDA
kr 165.49
kr 225.82
kr 286.15
67
EV/Revenue
kr 49.22
kr 76.97
kr 104.71
53
Asset-Based
NCAV (Graham)
kr 27.15
kr 36.39
kr 54.31
54
Growth DCF
Growth DCF
kr 56.06
kr 81.56
kr 111.93
79
Rev-Margin DCF
kr 50.26
kr 85.75
kr 127.47
72
Economic Profit
Residual Income
kr 38.69
kr 38.00
kr 39.72
76
ROIC Compounder
kr 28.18
kr 33.42
kr 37.68
72
Growth Earnings
Growth-Adj P/E
kr 46.08
kr 65.83
kr 85.57
67
Notify me when 0RF7 reaches fair value
Put 0RF7 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
56/100
Of which business quality 55 · Market factors (momentum, volatility) 85
Profitability
38
Margins and returns on capital today
Quality Growth
49
Are margins and returns improving?
Cashflow
66
Earnings quality: real cash, not paper profit
Fin. Strength
31
Balance sheet, leverage, solvency risk
Investment
76
Disciplined investing over empire-building
Low Volatility
68
Calm price path (market factor)
Momentum
88
Price trend over the last 3–12 months (market factor)
52W Momentum
100
Distance to the 52-week high (market factor)
Net Issuance
91
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
62/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+4.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.5%
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.3%
’12
’13
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+2.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+0.2%
Dividend (yield on the price)1.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.0.2% vs 14.2%, slowing
Profit margin 2018 to 2023 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 4%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+0.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about −1.7% a year for the price.
0RF7 screens overvalued: fair value 23% below the price. Compare with HCA Healthcare, Inc →
Compare Humana AB with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 246 stocks
Beats the industry median on 3/11 measures
Overall it trails its industry peers.
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: UK Stocks
- Valuation of the UK market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $431.63 | $597.97 | +39% |
| Fresenius SE FRE | €43.64 | €34.49 | −21% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 225.00 SAR | 109.45 SAR | −51% |
| Tenet Healthcare Corporation THC | $257.93 | $274.35 | +6% |
| IHH Healthcare Berhad, an investment holding company, 5225 | 8.03 MYR | 4.87 MYR | −39% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,889 | ₹2,908 | −67% |
| Encompass Health Corporation EHC | $123.47 | $94.47 | −23% |
| Fresenius Medical Care AG FMS | $22.27 | $45.84 | +106% |
| DaVita Inc DVA | $178.07 | $215.81 | +21% |
| Aier Eye Hospital Group 300015 | ¥7.91 | ¥10.86 | +37% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Humana AB (0RF7) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 56.30 versus a price of kr 72.70, about −23% upside (overvalued).
What is the fair value of 0RF7?
Our model-based fair value for Humana AB is kr 56.30 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 72.70.
What is the quality score of 0RF7?
Humana AB has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Humana AB (0RF7)?
Our model-based price target is the fair value of kr 56.30 (as of Sep 24, 2026) from 25 valuation models. Cautious scenario kr 54.65, optimistic scenario kr 70.38. It is a calculation from audited fundamentals, not an analyst target.
What is the Humana AB stock forecast for 2026?
Our models put fair value at kr 56.30, about −23% upside versus a price of kr 72.70 (overvalued). Cautious scenario kr 54.65, optimistic scenario kr 70.38. The calculation is refreshed regularly with new filings.
What is the revenue of Humana AB (0RF7)?
Humana AB reported trailing-twelve-month revenue of about 10.0B SEK (latest available figure, as of Sep 24, 2026).
Does Humana AB pay a dividend?
Humana AB currently shows a dividend yield of about 1.86% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Humana AB (0RF7)?
For today's price to be fair in a discounted-cash-flow model, Humana AB would have to grow free cash flow by +0.3 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.5 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 0RF7 use?
Our models discount Humana AB at 11.8 %: a base by market capitalisation (micro), damped by beta 0.04, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Humana AB that is +0.3 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Humana AB (0RF7) delivered so far?
Over the past 5 years revenue at Humana AB grew +7.5 % a year. The price currently implies +0.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Humana AB (0RF7) growing?
The median revenue growth in the sector is +7.2 % a year. That is the yardstick for the growth priced into Humana AB (+0.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Humana AB (0RF7)?
The free-cash-flow yield on the price is 12.97 %: that much free cash flow Humana AB produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Humana AB (0RF7)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Humana AB it is kr 56.30 per share (as of Sep 24, 2026), against a price of kr 72.70. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Humana AB stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0RF7 trades above its calculated fair value: price kr 72.70, fair value kr 56.30, a gap of about −23% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0RF7?
No. The price is what the market pays today (kr 72.70); the fair value is what the company's own numbers justify (kr 56.30). For Humana AB the two are kr 16.40 per share apart. That gap is exactly why we show both numbers side by side.
How much is Humana AB worth?
The market values Humana AB at about 3.5B SEK (market capitalisation, as of Sep 24, 2026). Per share that is kr 72.70; our models calculate a fair value of kr 56.30 per share.
What do the bullish and bearish scenarios say about 0RF7?
Our models span a range for Humana AB: cautious scenario kr 54.65, base kr 56.30, optimistic kr 70.38 per share (as of Sep 24, 2026, price kr 72.70). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0RF7?
Humana AB trades at a price-to-earnings ratio of 0.1 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 56.30 is built from several models across several years.
How solid is the balance sheet of Humana AB (0RF7)?
Balance-sheet figures for Humana AB (as of Sep 24, 2026): return on equity 5.5%, debt of 0.52 per unit of equity. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is 0RF7 from its 52-week high?
Humana AB trades at kr 72.70, at its 52-week high of kr 72.70 and 85% above the low of kr 39.34 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of kr 56.30 is for.
Which stocks are comparable to Humana AB?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Humana AB stock attractive at the current price?
The data as of Sep 24, 2026: price kr 72.70, calculated fair value kr 56.30 (−23%), Quality Score 56/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0RF7 calculated?
We run Humana AB through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 56.30, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Humana AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Humana AB (0RF7)?
The closing price on Oct 2, 2026 was kr 72.70. Our model-based fair value is kr 56.30, about −23% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Humana AB right now?
The price sits above even our optimistic bull case (kr 70.38). The favourable scenario is already priced in. Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Humana AB (0RF7) come from?
Earnings per share at Humana AB grew +13.9 % a year from 2012 to 2023. Broken into its drivers: revenue per share +9.2 %, EBIT margin −2.2 %, tax rate +3.0 %, residual (interest, one-offs) +3.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Humana AB
How large is the market capitalisation of Humana AB (0RF7)?
The market capitalisation of Humana AB is 3.5B SEK (≈ $346M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Humana AB (0RF7)?
Earnings per share at Humana AB are kr 5.00 (price ÷ EPS = P/E 0.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Humana AB (0RF7)?
The dividend yield of Humana AB is 1.9% (payout 27.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Humana AB (0RF7)?
The net margin of Humana AB is 1.8% (fiscal year 2023). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Humana AB (0RF7)?
The return on equity (ROE) of Humana AB is 5.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Humana AB (0RF7)?
On an EBIT basis the return on assets of Humana AB is 4.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Humana AB (0RF7)?
The operating margin of Humana AB is 1.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Humana AB (0RF7)?
Revenue at Humana AB is growing +3.0% versus a year earlier (3y avg +7.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Humana AB (0RF7)?
Earnings per share at Humana AB are growing −45.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Humana AB (0RF7) carry?
The net debt of Humana AB is 4.3B SEK (fiscal year 2023, ≈ 9.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Humana AB in the live analysis
One click puts Humana AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.